Nycomed puts off flotation until US recovers
This article was originally published in Clinica
Nycomed Amersham, which announced plans to float 10% of its life sciences business last year (see Clinica No 921, p 11), has chosen to put that plan on hold until market conditions in the US become more friendly to companies wishing to raise public capital.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.